Nestlé is sorting out its health activities


Despite gradually increasing sales in the United States for Palforzia since the end of 2021, the world food leader preferred to stop the costs. Federica Narancio/AP

The Swiss giant sells its peanut allergy medicine to Stallergènes.

Almost three years ago to the day, Nestle opened its purse strings wide to buy the American specialist in food allergy Aimmune, valued at 2.6 billion dollars (2.2 billion euros) at the time. Today, he adjusts the shot in health.

This Monday, the Swiss group known for its brands Nescafé, KitKat, Maggi and Purina, announced the sale of one of the American group’s flagship , Palforziato the Swiss biopharmaceutical group Stallergenes Greer, for an undisclosed sum. “Nestlé will receive milestone payments and royalties from Stallergenes Greer,” explained the Swiss giant succinctly in a press release.

Read alsoNestlé expands its project to fight deforestation in Côte d’Ivoire to other companies

Although the group’s managing director, Mark Schneider, has driven a major shift in Nestlé’s health since his arrival in 2017, this operation is not a surprise. Last year, the group with 98.8 billion euros in turnover announced the strategic review of this treatment against…

This article is for subscribers only. You have 80% left to discover.

Want to read more?

Unlock all items immediately.

Already subscribed?
Login



Source link

Leave a Reply